Bolt Biotherapeutics is developing immuno-oncology therapies to eliminate tumors. Many tumors create an immune-suppressive environment to prevent their clearance. Bolt is leveraging the precision of antibody targeting to activate both the immune response in the tumor microenvironment. By identifying immune-stimulating antibody conjugates (ISACs), which Bolt refers to as Boltbody, a localized anti-tumor immune cascade can be stimulated to offer personalized therapeutic options. Using this approach, Bolt can address difficult-to-treat solid tumors and generate long-term anti-tumor responses through immunological memory. Bolt’s lead candidate, BDC-1001, is a HER2 BoltBody ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors.